not be part of this report. reportu

Similar documents
Sadzobník kartových poplatkov firemné platobné karty / Schedule of Card Charges company payment cards

Attachment No. 1 Employees authorized for communication

AIFP CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS

Pfizer Hellas SA PRIMA/EFPIADisclosure Code Transparency Report

Methodological Note. - Merck Oy Finland -

Pfizer 2017 Disclosure Code Transparency Report

Methodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3

Disclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi

EFPIA Disclosure in Luxembourg Methodology Note - Boehringer Ingelheim

Transfer of Value Disclosure Report as per National Legislation

Christiana Serugová, Partner, Tax Leader at PwC Tel.:

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

Novartis Methodological Note

Sanofi-Aventis Bulgaria EOOD Methodological Note

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP

Novartis Methodological Note

DISCLOSURES OF TRANSFERS OF VALUE: SUMMARY OF METHODOLOGY

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements

Any healthcare professional and healthcare organisation whose primary practice, principal professional address or place of incorporation

Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur

Gilead Transparency Reporting Methodological Note

LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements

ARPIM HCP/HCO DISCLOSURE CODE

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Gilead Transparency Reporting Methodological Note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note

Bristol-Myers Squibb (BMS) Methodology Document in support of the EFPIA transparency disclosure code for HCP/HCO transfers of value pertaining to 2017

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016

Any healthcare professional and healthcare organization whose primary practice, principal professional address or place of incorporation

Gilead Transparency Reporting Methodological Note

Gilead Transparency Reporting Methodological Note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Novartis Methodological Note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office

AbbVie Ltd 2015 ABPI Transparency Disclosure Methodological Notes

Novartis Methodological Note

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note

Novartis Methodological Note

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire

Pharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland

ABPI Disclosure Methodological Note March 2017

Pfizer 2016 Disclosure Code Transparency Report

OTSUKA PHARMACEUTICAL EUROPE LTD ( OTSUKA EUROPE ) EFPIA DISCLOSURE: AUSTRIA METHODOLOGY NOTE APPLICABLE TO TRANSFERS OF VALUE.

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note

Novartis Methodological Note

General Terms and Conditions ( GTC ) for VAT and Excise Duty Refund Services by NIKOSAX for Customers of SLOVNAFT, a.s.

Takeda Belgium - Methodological note 2015

Pfizer 2015 Disclosure Code Transparency Report

Gilead Transparency Reporting Methodological Note

FREQUENTLY ASKED QUESTIONS SUNSHINE ACT

Novartis Methodological Note

Novartis Methodological Note

Príloha č. 3: k Cenníku služieb JELLYFISH Finport Professional a Individuálne riadené portfólio

Poradie najväčších lízingových spoločností v SR podľa typu predmetu za 1. štvrťrok 2014 (v obstarávacích cenách bez DPH v tis. )

EFPIA Transparency / LIF public reporting of transfers of value. Sobi Methodology Note Transfers of Value (reported 2017) Sweden

Ministry of Health and Long-Term Care Proposed new regulation made under the Health Sector Payment Transparency Act, 2017

Medicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements. Samsung Bioepis Methodology Note

FREQUENTLY ASKED QUESTIONS SUNSHINE ACT

CEGEDIM produktové protfólio Hotel Kaskády

RULES GOVERNING DRUG INFORMATION

Title: Methodological Note

Title: Methodological Note

EFPIA Disclosure Code 2016 Disclosures Shire Pharmaceuticals (including Baxalta US Inc.)

Any questions relating to this Methodology Note and / or the report should be directed to:

Mitsubishi Tanabe Pharma Group Methodology. Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe

EFPIA HCP/HCO DISCLOSURE CODE

Global Compliance Policy on Due Diligence and Interactions with Third Party Representatives

This document explains the methodology underlying Roche s EFPIA disclosure

Merz Pharma GmbH & Co. KGaA. Methodological Note. Transfer of Value Disclosure Report Belgium for the Calendar Year 2017

DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS IN THE UK

Novartis Pharma Austria Methodological Note

DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS Publication Date:

SLOVAK REPUBLIC Secondary legislation

Transparency & related issues Some industry considerations

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

for contact and cooperation between patient oganisations and the pharmaceutical industry The agreement, objectives and parties

Johnson & Johnson Financial Conflicts of Interest Policy

APPLICATION REGULATIONS OF THE CODE OF PRACTICE ON THE PROMOTION OF MEDICINAL PRODUCTS

DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS

Ethical Rules for Collaboration between Patient Groups, etc. and the Pharmaceutical Industry

SLOVAK TAX NEWS 2/2011

CODE OF CONDUCT. Medicines for Europe. Follow us on

Q&A on the FSA Code of Conduct on Transparency of Collaboration with Healthcare Professionals

KOMISIA EURÓPSKYCH SPOLOČENSTIEV. Návrh NARIADENIE EURÓPSKEHO PARLAMENTU A RADY

Transcription:

The methodology of Merck spol. s r.o. for publishing value transfers to healthcare professionals and healthcare organisations according to the AIFP Code of Ethics (in line with the EFPIA Disclosure Code). Any and all direct and indirect transfers of values received by a healthcare professional or a healthcare organisation shall be subject to publication. Transfers of values that are subject to publication according to Act No. 362/2011 on Drugs and Medical Devices and that were reported for 2016 at http://www.nczisk.sk/medicalstatistics/publication_based_onact_362-2011_on_drugs_medical_devices shall not be part of this report. The submitted report contains only those transfers of values for 2016 (1.1.2016-31.12.2016) that, according to the differences between the EFPIA definition and local legislation, were not published; the date of payment in case of financial fulfilment and the date of realisation in case of nonfinancial fulfilment shall be decisive for inclusion into the period. Financial transfers shall be published as gross payments, including tax. Values of non-financial transfers shall be published in the form of the total amount, including VAT. Metodika spoločnosti Merck spol. s r.o. pre zverejňovanie prevodov hodnôt k zdravotníckym pracovníkom a zdravotníckym organizáciám podľa Etického kódexu AIFP ( v súlade s EFPIA Disclosure Code). Zverejňovaniu podliehajú všetky priame a nepriame prevody hodnôt, ktorých príjemcom je zdravotnícky pracovník alebo zdravotnícka organizácia. Prevody hodnôt, ktoré podliehajú zverejňovaniu podľa Zákona č. 362/2011 o liekoch a zdravotníckych pomôckach a boli za rok 2016 nahlásené na http://www.nczisk.sk/medicinskastatistika/zverejnovanie_na_zakladezakona_362-2011_liekoch_zdravotnickych_pomo ckach nie sú súčasťou tohto reportu Predkladaná správa obsahuje len tie prevody hodnôt za rok 2016 (1.1.2016-31.12.2016), ktoré podľa rozdielov v definícii EFPIA a lokálnej legislatívy neboli zverejnené; pre zaradenie do obdobia je rozhodujúci dátum platby pri peňažnom plnení a dátum realizácie pri nepeňažnom plnení. Peňažné prevody sú zverejnené ako hrubé platby vrátane dane. Hodnoty nepeňažných prevodov sú zverejnené vo forme celkovej sumy, vrátane DPH.

Definitions Definície A Healthcare Professional (HP) shall mean any individual who is a member of a healthcare, stomatological, pharmaceutical or nursing profession or another individual who, as part of his or her professional activity, may prescribe, purchase, provide, recommend or administer a drug and whose main practice, main address of their profession s performance or place of its registered office is in the Slovak Republic. In order to exclude any doubts, the definition of a healthcare professional shall also include: any and all official or employee of a governmental agency or another organisation (either in the public or private sector) who may prescribe, purchase, provide or administer drugs and any and all employees whose main activity is the performance of the profession of a healthcare professional, while, however, whole-sale distributors shall be excluded. A Healthcare Organisation (HO) shall mean any and all legal entity/ies that is an association or an organisation providing healthcare, a health or research association or organisation (regardless of its legal and organisational form), such as a hospital, clinic, foundation, university or other education institution or education company (also e.g. the Slovak Medical Society), the registered office place of establishment or main place of operation of which is in the Slovak Zdravotnícky pracovník (ZP) znamená každú fyzickú osobu, ktorá je členom zdravotníckej, stomatologickej, farmaceutickej alebo ošetrovateľskej profesie, alebo iná osoba, ktorá v rámci svojej odbornej činnosti môže predpisovať, kupovať, poskytovať, odporúčať, alebo podávať liek, a ktorej hlavná prax, hlavná adresa výkonu povolania alebo miesto jej sídla je v Slovenskej republike. Pre vylúčenie pochybností, definícia zdravotníckeho pracovníka zahŕňa aj: každého úradníka alebo zamestnanca vládnej agentúry alebo inej organizácie (či už vo verejnom alebo súkromnom sektore), ktorí môžu predpisovať, nakupovať, poskytovať alebo podávať lieky, a každého zamestnanca, ktorého hlavnou činnosťou je výkon povolania zdravotníckeho pracovníka, pričom ale vylučuje veľkodistribútorov liekov. Zdravotnícka organizácia (ZO) znamená každú právnickú osobu, ktorá je združením alebo organizáciou poskytujúcou zdravotnú starostlivosť, zdravotné alebo výskumné združenie alebo organizácia (bez ohľadu na právnu alebo organizačnú formu), ako napríklad nemocnica, klinika, nadácia, univerzita alebo iná vzdelávacia inštitúcia alebo vzdelávacia spoločnosť (aj napr. Slovenská lekárska spoločnosť), ktorej obchodné sídlo, miesto založenia

Republic, or through which one or more healthcare professionals provide services. alebo hlavné miesto prevádzky je v Slovenskej republike alebo prostredníctvom ktorej poskytuje služby jeden alebo viac zdravotníckych pracovníkov. Individual categories of published transfers Jednotlivé kategórie zverejnených prevodov Transfers of values to healthcare organisations Subsidies and grants Donations and grants to healthcare organisations for the purposes of supporting healthcare, including donations and grants (financial resources or material benefits) to institutions, organisations or associations consisting of healthcare professionals that provide healthcare. Prevody hodnôt na zdravotnícke organizácie Dotácie a granty Dary a granty pre zdravotnícke organizácie za účelom podpory zdravotnej starostlivosti, vrátane darov a grantov (peňažné prostriedky alebo vecné pôžitky) inštitúciám, organizáciám alebo združeniam, ktoré pozostávajú zo zdravotníckych pracovníkov, a/alebo ktoré poskytujú zdravotnú starostlivosť. Contributions to costs of events Príspevky na náklady podujatí Contributions to costs related to a professional event realised through a healthcare organisation or third parties, including sponsoring of healthcare professionals for the purposes of participation at professional events: i. Registration fees; ii. Sponsorship agreements with healthcare organisations or third parties delegated by healthcare organisations to organise a professional event and iii. Travel expenses and accommodation expenses; Príspevky na náklady súvisiace s odborným podujatím, realizované prostredníctvom zdravotníckej organizácie alebo tretích strán, vrátane sponzorstva zdravotníckych pracovníkov za účelom účasti na odborných podujatiach: i. registračné poplatky; ii. sponzorské zmluvy so zdravotníckymi organizáciami alebo tretími stranami, ktoré zdravotnícke organizácie poverili organizáciou odborného podujatia a iii. cestovné výdavky a výdavky za ubytovanie

iv. Purchase of services during an event, such as the leasing of exhibition premises, purchase of advertisement space, advertising in materials of the event, etc., shall also be considered as a contribution to the costs of the event; Fees for services and consultations Transfers of values arising or relating to agreements between companies and institutions, organisations or associations of healthcare professionals, based on which such institutions, organisations or associations provide any type or service or any type of funding to the company, not included in the previous categories. The remuneration and transfers of values concerning expenditures agreed in a written agreement related to the agreed activity shall be published as two individual amounts (payment for the service + paid costs related to the service's provision). iv. nákup služieb počas podujatia, ako prenájom výstavnej plochy, nákup reklamného priestoru, inzercia v materiáloch podujatia a pod. sa tiež považuje za príspevok na náklady podujatia Poplatky za služby a konzultácie Prevody hodnoty vyplývajúce z alebo súvisiace so zmluvami medzi spoločnosťou a inštitúciami, organizáciami alebo združeniami zdravotníckych pracovníkov, na základe ktorých takéto inštitúcie, organizácie alebo združenia poskytujú spoločnosti akýkoľvek typ služieb, alebo akýkoľvek iný druh financovania, ktorý nie je zaradený do predchádzajúcich kategórií. Odmena i prevody hodnoty týkajúce sa výdavkov dohodnutých v písomnej zmluve vzťahujúcej sa na dohodnutú činnosť budú zverejňované ako dve samostatné sumy (platba za službu + uhradené náklady súvisiace s poskytnutím služby). Transfers of values to healthcare professionals Contribution to costs of events Contribution to costs related to a professional event: i. Registration fees; and ii. Travel expenses and accommodation expenses Fees for services and consultations Transfers of values resulting in or relating to agreements between companies and healthcare professionals based on which healthcare professional Prevody hodnôt na zdravotníckych pracovníkov Príspevok na náklady podujatí Príspevok na náklady spojené s odborným podujatím: i. registračné poplatky; a ii. cestovné výdaje a výdaje na ubytovanie Poplatky za služby a konzultácie Prevody hodnoty vyplývajúce z alebo súvisiace so zmluvami medzi spoločnosťou a zdravotníckymi pracovníkmi, na základe ktorých

provide members with any kind of service or any other type of funding that is not included in the previous categories. The remuneration and transfers of values concerning expenses agreed in the written agreement related to the agreed activity shall be published as two separate amounts (payment for service + paid costs related to the provision of the service, if incurred, e.g. payment for professional training / lecture + payment of travel expenses to the place of training). Aggregate publication Transfers of values when it is not possible to individually publish certain information due to statutory reasons (e.g. consent to the publication of personal data not provided) shall be published by the company for the period of reporting as an aggregate amount corresponding to such transfers of value. Such aggregate publication shall identify, for each category, the number of recipients stated in such publication, namely in absolute numbers and as a percentage of all recipients and the aggregate amount corresponding to the transfers of values to such recipients. Transfers of value in research and development The company publishes transfers of value concerning research and development for the given period in the aggregate statement as one amount. Costs published according to Act No. 362/2011 on Drugs and Medical Devices are not part of this report. zdravotnícki pracovníci poskytujú členom akýkoľvek typ služieb, alebo akýkoľvek iný druh financovania, ktorý nie je zaradený do predchádzajúcich kategórií. Odmena i prevody hodnoty týkajúce sa výdavkov dohodnutých v písomnej zmluve vzťahujúcej sa na dohodnutú činnosť budú zverejňované ako dve samostatné sumy (platba za službu + uhradené náklady súvisiace s poskytnutím služby ak boli vynaložené, napr. platba za odborné školenie / prednášku + úhrada cestovného do miesta školenia). Súhrnné zverejnenie Prevod hodnoty, kedy nie je možné jednotlivo zverejniť určité informácie zo zákonných dôvodov (napr. neposkytnutý súhlas so zverejnením osobných údajov), zverejňuje spoločnosť za obdobie nahlasovania ako súhrnnú sumu pripadajúcu na takéto prevody hodnoty. Takéto súhrnné zverejnenie identifikuje pre každú kategóriu počet príjemcov uvedených v takomto zverejnení, a to v absolútnych číslach a ako percento zo všetkých príjemcov a súhrnnú sumu pripadajúcu na prevody hodnoty takýmto príjemcom. Prevody hodnoty vo výskume a vývoji Spoločnosť zverejňuje za dané obdobie v súhrnnom vyjadrení prevody hodnoty týkajúce sa výskumu a vývoja ako jednu sumu. Náklady, ktoré sú zverejňované podľa Zákona č. 362/2011 o liekoch a zdravotníckych pomôckach, nie sú súčasťou tohto reportu.